title: Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer.
abstract: BACKGROUND
  A dendritic cell vaccine has been developed as a novel strategy for generating antitumor immunity in the treatment of cancer. The purpose of this study was to assess the maximal tolerated dose, safety, and immunologic response of a new dendritic cell vaccine (DC-Vac) into which tumor lysate was loaded by electroporation and pulse in patients with advanced non-small cell lung cancer (NSCLC).
  
  
  METHODS
  Fifteen patients with inoperable stage III or IV NSCLC were assigned to cohorts that received 3, 6, or 12 × 10(6) DC-Vac intradermally 3 times at 2 week intervals. We also evaluated immunologic and tumor responses.
  
  
  RESULTS
  The maximum dose of DC-Vac (12 × 10(6)) was shown to be safe. In 5 of 9 patients, the vaccine resulted in increased interferon (IFN)-γ production by CD8+ cells after exposure to tumor lysate. Additionally, there were mixed responses which do fulfill progressive disease definition but demonstrate some clinical benefit in two patients.
  
  
  CONCLUSIONS
  The administration of tumor lysate-loaded autologous dendritic cells by electroporation and pulse was non-toxic and induced immunologic responses to tumor antigens. The two mixed tumor responses which were achieved may represent a potential benefit of this new DC-Vac.
authors.affiliation: Department of Internal Medicine, Dong-A University College of Medicine, 3-Ga Dongdaeshin-dong, Seo-gu, Busan 602-715, Republic of Korea.
authors.forename: Soo-Jung
authors.initials: SJ
authors.lastname: Um
authors.forename: Young Jin
authors.initials: YJ
authors.lastname: Choi
authors.forename: Ho-Jin
authors.initials: HJ
authors.lastname: Shin
authors.forename: Cheol Hun
authors.initials: CH
authors.lastname: Son
authors.forename: You-Soo
authors.initials: YS
authors.lastname: Park
authors.forename: Mee Sook
authors.initials: MS
authors.lastname: Roh
authors.forename: Yun Seong
authors.initials: YS
authors.lastname: Kim
authors.forename: Young Dae
authors.initials: YD
authors.lastname: Kim
authors.forename: Soo-Keol
authors.initials: SK
authors.lastname: Lee
authors.forename: Min Ho
authors.initials: MH
authors.lastname: Jung
authors.forename: Min Ki
authors.initials: MK
authors.lastname: Lee
authors.forename: Choonhee
authors.initials: C
authors.lastname: Son
authors.forename: Pil Jo
authors.initials: PJ
authors.lastname: Choi
authors.forename: Jooseop
authors.initials: J
authors.lastname: Chung
authors.forename: Chi-Dug
authors.initials: CD
authors.lastname: Kang
authors.forename: Eun-Yup
authors.initials: EY
authors.lastname: Lee
mesh_terms: D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000276:immunology* / Q000378:metabolism; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D019496:Cancer Vaccines; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D003713:Dendritic Cells / Q000276:immunology / Q000378:metabolism* / Q000473:pathology / Q000637:transplantation; D018450:Disease Progression; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000378:metabolism; D008175:Lung Neoplasms / Q000276:immunology / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D008213:Lymphocyte Activation; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009367:Neoplasm Staging; D014182:Transplantation, Autologous
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D007371:Interferon-gamma